Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Max J M Silvis"'
Autor:
Aernoud T L Fiolet, Max J M Silvis, Tjerk S J Opstal, Willem A Bax, Frans A L van der Horst, Arend Mosterd, Dominique de Kleijn, Jan H Cornel
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237665 (2020)
AimsInflammation plays a pivotal role in atherothrombosis. Colchicine is an anti-inflammatory drug that may attenuate this process. Cardiovascular protective effects of anti-inflammatory drugs, however, seem to be limited to patients with a biochemic
Externí odkaz:
https://doaj.org/article/b38a1965d26b4720abe59462e5099bcb
Autor:
Mirthe Dekker, Farahnaz Waissi, Joelle van Bennekom, Max J M Silvis, Nathalie Timmerman, Arjan H Schoneveld, Diederick E Grobbee, Robbert J de Winter, Arend Mosterd, Leo Timmers, Dominique P V de Kleijn
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237036 (2020)
BackgroundDespite the use of high-sensitive cardiac troponin there remains a group of high-sensitive cardiac troponin negative patients with unstable angina with a non-neglectable risk for future adverse cardiovascular events, emphasising the need fo
Externí odkaz:
https://doaj.org/article/383929d67bbf4807b02097add5e6b0d9
Autor:
Max J. M. Silvis, Evelyne J. Demkes, Leo Timmers, Fatih Arslan, Saskia C. A. de Jager, Joost P. G. Sluijter, Arend Mosterd, Dominique P. V. de Kleijn, Lena Bosch, Gerardus P. J. van Hout
Publikováno v:
Biomedicines, Vol 10, Iss 12, p 3056 (2022)
NLRP3-inflammasome-mediated signaling is thought to significantly contribute to the extent of myocardial damage after myocardial infarction (MI). The purpose of this study was to investigate the effects of the NLRP3-inflammasome inhibitor IZD334 on c
Externí odkaz:
https://doaj.org/article/8797b0c53dd94455a8ff3413276c725f
Autor:
Amber van Broekhoven, Niekbachsh Mohammadnia, Max J. M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Willem A. Bax, Jan G. P. Tijssen, Dominique P. V. de Kleijn, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel
Publikováno v:
Clinical drug investigation, 42(11), 977-985. Adis International Ltd
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Contains fulltext : 288089.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7e75f557f8750b00f611a1192bac17
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
Publikováno v:
Netherlands Heart Journal
Netherlands Heart Journal, 30, 1, pp. 25-37
Netherlands Heart Journal, 30, 25-37
Netherlands Heart Journal, 30, 1, pp. 25-37
Netherlands Heart Journal, 30, 25-37
Contains fulltext : 249997.pdf (Publisher’s version ) (Open Access) Patients with coronary disease remain at high risk for future cardiovascular events, even with optimal risk factor modification, lipid-lowering drugs and antithrombotic regimens. A
Autor:
Arif A Khokhar, Carlo Zivelonghi, Mirthe Dekker, Geert E. Leenders, Roberto Ferrari, F Sgura, Stefan Verheye, Giuseppe Tarantini, Alessandro Cafaro, Jan-Peter van Kuijk, Stefano Guarracini, Christoph Liebetrau, Maayan Konigstein, Sergio Berti, Dan Ioanes, Matjaž Bunc, Pieter R. Stella, Leo Timmers, Issameddine Ajmi, Antonio Colombo, Shmuel Banai, Ranil de Silva, Francesco Ponticelli, Pierfrancesco Agostoni, Claudio Rapezzi, Max J. M. Silvis, Alfonso Ielasi, Matteo Tebaldi, M. Ciardetti, Jan Sebastian Wolter, Michele Di Mauro, Kevin Cheng, Gianluca Campo, Simon Redwood, Guglielmo Gallone, Francesco Giannini, Tiffany Patterson, Federico De Marco, Gianpiero D'Amico, Steffen Schnupp, Steven Lindsay
Publikováno v:
International Journal of Cardiology. 337:29-37
Introduction Refractory angina (RA) is considered the end-stage of coronary artery disease, and often has no interventional treatment options. Coronary sinus Reducer (CSR) is a recent addition to the therapeutic arsenal, but its efficacy has only bee
Autor:
Amber, van Broekhoven, Niekbachsh, Mohammadnia, Max J M, Silvis, Jonathan, Los, Aernoud T L, Fiolet, Tjerk S J, Opstal, Arend, Mosterd, John W, Eikelboom, Stefan M, Nidorf, Charley A, Budgeon, Elizabeth, Byrnes, Willem A, Bax, Jan G P, Tijssen, Dominique P V, de Kleijn, Peter L, Thompson, Saloua, El Messaoudi, Jan H, Cornel
Publikováno v:
Clinical drug investigation. 42(11)
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchi
Autor:
Dominique P.V. de Kleijn, Max J. M. Silvis, Aernoud T L Fiolet, Lena Bosch, Joyce Mj Visser, Leo Timmers, Mirthe Dekker, Marlijn S Jansen, Martijn M. J. van Nieuwburg, Gerardus P.J. van Hout
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders
Background Preclinical models that resemble the clinical setting as closely as possible are essential in translating promising therapies for the treatment of acute myocardial infarction. Closed chest pig left anterior descending coronary artery (LAD)
Autor:
J.P. van Kuijk, P. A. F. M. Doevendans, Pierfrancesco Agostoni, Pieter R. Stella, Dominique P.V. de Kleijn, Max J. M. Silvis, Mirthe Dekker, Carlo Zivelonghi, Leo Timmers, Geert E. Leenders
Publikováno v:
Netherlands Heart Journal
Background Refractory angina is a growing and major health-care problem affecting millions of patients with coronary artery disease worldwide. The Coronary Sinus Reducer (CSR) is a device that may be considered for the relief of symptoms of refractor
Autor:
Arjan H. Schoneveld, Nikolas Lessmann, Farahnaz Waissi, Max J. M. Silvis, Robbert J. de Winter, Mirthe Dekker, Joelle van Bennekom, Ivana Išgum, Arend Mosterd, Leo Timmers, Dominique P.V. de Kleijn, B. K. Velthuis, Gerard Pasterkamp
Publikováno v:
Scientific reports, 11(1):18946. Nature Publishing Group
Scientific Reports, 11
Scientific Reports
Scientific Reports, 11, 1
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11:18946. Nature Publishing Group
Scientific Reports, 11
Scientific Reports
Scientific Reports, 11, 1
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11:18946. Nature Publishing Group
Plasma osteoprotegerin (OPG) and vascular smooth muscle cell (VSMC) derived extracellular vesicles (EVs) are important regulators in the process of vascular calcification (VC). In population studies, high levels of OPG are associated with events. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2184ef900cfc9d4b64121b911e993be9
https://pure.amc.nl/en/publications/high-levels-of-osteoprotegerin-are-associated-with-coronary-artery-calcification-in-patients-suspected-of-a-chronic-coronary-syndrome(6a31fa57-b672-46d7-a52b-150902aa240c).html
https://pure.amc.nl/en/publications/high-levels-of-osteoprotegerin-are-associated-with-coronary-artery-calcification-in-patients-suspected-of-a-chronic-coronary-syndrome(6a31fa57-b672-46d7-a52b-150902aa240c).html